Mohammed Rassool
A5034474153- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
- HIV-related health complications and treatments
- Infectious Diseases and Tuberculosis
- Mycobacterium research and diagnosis
- Diagnosis and treatment of tuberculosis
- COVID-19 Clinical Research Studies
- Hepatitis C virus research
- Health Systems, Economic Evaluations, Quality of Life
- Pharmacological Effects and Toxicity Studies
- Hepatitis B Virus Studies
- Mental Health Treatment and Access
- SARS-CoV-2 and COVID-19 Research
- Syphilis Diagnosis and Treatment
- Genital Health and Disease
- Cytomegalovirus and herpesvirus research
- Adolescent and Pediatric Healthcare
- Pregnancy and Medication Impact
- Pregnancy and preeclampsia studies
- Cervical Cancer and HPV Research
- Cancer therapeutics and mechanisms
Africa Health Research Institute
2023-2025
University of the Witwatersrand
2013-2024
Helen Joseph Hospital
2013-2024
Perinatal HIV Research Unit
2019-2022
Instituut voor Tropische Geneeskunde
2022
Mongolian University of Life Sciences
2022
Phthisiopneumology Institute "Chiril Draganiuc"
2022
MRC Clinical Trials Unit at UCL
2022
National Institute of Research in Tuberculosis
2022
B.J. Medical College
2022
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a acceptable side-effect profile than current needed.We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial to evaluate the efficacy safety of three 24-week, for tuberculosis. Patients in Belarus, South Africa, Uzbekistan who were 15 years age or older had pulmonary tuberculosis enrolled. stage 2 trial, 24-week regimen bedaquiline,...
SummaryBackgroundThe broad use of bedaquiline and pretomanid as the mainstay new regimens to combat tuberculosis is a risk due increasing resistance. We aimed assess safety, bactericidal activity, pharmacokinetics BTZ-043, first-in-class DprE1 inhibitor with strong activity in murine models.MethodsThis open-label, dose-expansion, randomised, controlled, phase 1b/2a trial was conducted two specialised sites Cape Town, South Africa. Adults aged 18–64 years newly diagnosed pulmonary sensitive...
BackgroundNew anti-tuberculosis regimens that are shorter, simpler, and less toxic than those currently available needed as part of the global effort to address tuberculosis epidemic. We aimed investigate bactericidal activity safety profile combinations bedaquiline, pretomanid, moxifloxacin, pyrazinamide in first 8 weeks treatment pulmonary tuberculosis.MethodsIn this multicentre, open-label, partially randomised, phase 2b trial, we prospectively recruited patients with drug-susceptible or...
BackgroundCurrent tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, improve long-term survival, shorten treatment duration; however, few have been tested clinically. Therefore, we aimed to assess safety preliminary efficacy of four for tuberculosis.MethodsIn this prospective, open-label, phase 2, randomised controlled trial, pulmonary were recruited at three...
We report a 23% asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) Omicron carriage rate in participants being enrolled into clinical trial South Africa, 15-fold higher than trials before Omicron. also found lower CD4 + T-cell counts persons with human immunodeficiency virus (HIV) strongly correlated increased odds of SARS-CoV-2 polymerase chain reaction (PCR) positive.
BackgroundAround 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety efficacy TB-PRACTECAL trial, evaluating oral regimens for tuberculosis.MethodsThis open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital community sites in Uzbekistan, Belarus, South Africa,...
The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting bactericidal effect on non-replicating bacilli. Based results from preclinical and early clinical studies, four-drug combination of bedaquiline, moxifloxacin, pyrazinamide (BPaMZ) regimen was identified treatment-shortening for both drug-susceptible (DS) drug-resistant (DR) TB. This trial aimed...
Background. Evaluation of pretreatment HIV genotyping is needed globally to guide treatment programs. We examined the association (baseline) drug resistance and subtype with virologic failure in a multinational, randomized clinical trial that evaluated 3 antiretroviral (ART) regimens included resource-limited setting sites. Methods. Pol was performed nested case-cohort study including 270 randomly sampled participants (subcohort), 218 additional failing ART (case group). Failure defined as...
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical public health practice. purpose the journal disseminate original research results support high-level learning Medicine. It publishes articles, editorials, case reports/case series, reviews state-of-the-art practice correspondence.
To compare treatment outcomes by starting CD4 cell counts using data from the Comprehensive International Program of Research on AIDS-South Africa trial.An observational cohort study.Patients presenting to primary care clinics with below 350 cells/microl were randomized either doctor or nurse-managed HIV and followed for at least 2 years after antiretroviral therapy (ART) initiation. Clinical laboratory compared baseline counts.Eight hundred twelve patients a median 27.5 months 36% initiated...
Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but factors for in these unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis adults initiating ART CD4+ T-cell counts less than 50 cells/μl to evaluate within 48 weeks initiation. Cox proportional hazards models were fit characteristics baseline and 4 including the week...
Abstract Background Tenofovir/lamivudine/dolutegravir (TLD) is widely prescribed worldwide. We report virologic and resistance outcomes for patients initiating or switching to TLD. Methods A prospective observational study was performed at 13 AIDS Clinical Trials Group (ACTG) sites in six PEPFAR-supported countries coincident with TLD rollout. This includes results from two groups: Gp1 were virally suppressed on NNRTI-based ART Gp2 ART-naïve initiation. The primary objective estimate the...
<title>Abstract</title> <bold>Background</bold> Newer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery lung function during TB treatment and prevent post-TB disease. <bold>Methods</bold> panTB-HM trial assesses capacity containing oxazolidinone sutezolid anti-oxidant N-acetylcysteine meet target criteria proposed by WHO for indications a phase 2C trial. <bold>Discussion</bold> This is ground-breaking...
Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective the AA5208/OCTANE trial was to compare efficacy NVP-based versus lopinavir/ritonavir (LPV/r)-based initial ART.In seven African countries (Botswana, Kenya, Malawi, South Africa, Uganda, Zambia, and Zimbabwe), 500 antiretroviral-naïve HIV-infected women with CD4<200 cells/mm(3) were enrolled into a two-arm randomized initiate open-label ART tenofovir (TDF)/emtricitabine (FTC) once/day...
Raltegravir 1200mg (2×600mg tablets) once daily (QD) demonstrated noninferior efficacy and similar safety to raltegravir 400mg twice (BID) at week 48 of the ONCEMRK trial. Here, we report 96 results from this study.ONCEMRK is a phase 3, multicenter, double-blind, noninferiority trial comparing QD with BID in treatment-naive HIV-1-infected adults. Participants were assigned (2:1) 2×600mg or BID, both emtricitabine tenofovir disoproxil fumarate (FTC/TDF) for weeks. Randomization was stratified...
Abstract Background Linezolid is an effective, but toxic anti-tuberculosis drug that currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid novel oxazolidinone developed by LegoChem Biosciences Inc. has been evaluated up to phase 2a clinical trials. Since toxicity can occur late in treatment, and PanACEA Consortium designed DECODE be innovative dose-ranging study with long-term...
Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of dolutegravir (TLD+50) required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on effectiveness TLD+50 in individuals TB/human immunodeficiency virus (HIV). We performed a prospective, observational cohort study at 12 sites Haiti, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Participants starting TLD TB treatment were...